AIM:CLIN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£820.8m

Last Updated

2021/07/29 21:15 UTC

Data Sources

Company Financials +

Executive Summary

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. More Details


Snowflake Analysis

Good value with reasonable growth potential.


Similar Companies

Share Price & News

How has Clinigen Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLIN is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CLIN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

0.5%

CLIN

-0.7%

GB Life Sciences

1.6%

GB Market


1 Year Return

-16.6%

CLIN

13.3%

GB Life Sciences

21.7%

GB Market

Return vs Industry: CLIN underperformed the UK Life Sciences industry which returned 15.7% over the past year.

Return vs Market: CLIN underperformed the UK Market which returned 18.5% over the past year.


Shareholder returns

CLINIndustryMarket
7 Day0.5%-0.7%1.6%
30 Day-5.7%-7.1%0.4%
90 Day-29.4%-24.8%2.0%
1 Year-15.6%-16.6%13.8%13.3%27.2%21.7%
3 Year-39.7%-41.4%10.1%8.3%14.3%1.3%
5 Year-4.8%-8.5%45.5%42.6%40.9%13.8%

Long-Term Price Volatility Vs. Market

How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinigen Group undervalued compared to its fair value and its price relative to the market?

46.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLIN (£6.03) is trading below our estimate of fair value (£11.3)

Significantly Below Fair Value: CLIN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLIN is good value based on its PE Ratio (62.1x) compared to the UK Life Sciences industry average (63.6x).

PE vs Market: CLIN is poor value based on its PE Ratio (62.1x) compared to the UK market (23.9x).


Price to Earnings Growth Ratio

PEG Ratio: CLIN is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: CLIN is good value based on its PB Ratio (1.8x) compared to the GB Life Sciences industry average (4.3x).


Future Growth

How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

31.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLIN's forecast earnings growth (31.4% per year) is above the savings rate (0.9%).

Earnings vs Market: CLIN's earnings (31.4% per year) are forecast to grow faster than the UK market (16.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CLIN's revenue (10.1% per year) is forecast to grow faster than the UK market (5.4% per year).

High Growth Revenue: CLIN's revenue (10.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLIN's Return on Equity is forecast to be low in 3 years time (16.3%).


Past Performance

How has Clinigen Group performed over the past 5 years?

9.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLIN has a large one-off loss of £34.1M impacting its December 31 2020 financial results.

Growing Profit Margin: CLIN's current net profit margins (2.5%) are lower than last year (2.9%).


Past Earnings Growth Analysis

Earnings Trend: CLIN has become profitable over the past 5 years, growing earnings by 9.7% per year.

Accelerating Growth: CLIN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CLIN had negative earnings growth (-8.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-8.5%).


Return on Equity

High ROE: CLIN's Return on Equity (2.9%) is considered low.


Financial Health

How is Clinigen Group's financial position?


Financial Position Analysis

Short Term Liabilities: CLIN's short term assets (£235.6M) exceed its short term liabilities (£136.2M).

Long Term Liabilities: CLIN's short term assets (£235.6M) do not cover its long term liabilities (£447.6M).


Debt to Equity History and Analysis

Debt Level: CLIN's debt to equity ratio (89.6%) is considered high.

Reducing Debt: CLIN's debt to equity ratio has increased from 48% to 89.6% over the past 5 years.

Debt Coverage: CLIN's debt is well covered by operating cash flow (21.6%).

Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (5.9x coverage).


Balance Sheet


Dividend

What is Clinigen Group current dividend yield, its reliability and sustainability?

1.26%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CLIN's dividend (1.26%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.3%).

High Dividend: CLIN's dividend (1.26%) is low compared to the top 25% of dividend payers in the UK market (3.92%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, CLIN has been paying a dividend for less than 10 years.

Growing Dividend: CLIN's dividend payments have increased, but the company has only paid a dividend for 8 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (78.4%), CLIN's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CLIN's dividends in 3 years are forecast to be thoroughly covered by earnings (13.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Shaun Chilton (53 yo)

4.67yrs

Tenure

UK£1,489,000

Compensation

Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016 & has the responsibility for the Group achieving its KPIs and plays a central role in setting the...


CEO Compensation Analysis

Compensation vs Market: Shaun's total compensation ($USD2.08M) is above average for companies of similar size in the UK market ($USD970.45K).

Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLIN's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: CLIN's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Clinigen Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinigen Group plc
  • Ticker: CLIN
  • Exchange: AIM
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£820.753m
  • Shares outstanding: 133.02m
  • Website: https://www.clinigengroup.com

Number of Employees


Location

  • Clinigen Group plc
  • Pitcairn House
  • Crown Square
  • Burton-on-Trent
  • Staffordshire
  • DE14 2WW
  • United Kingdom

Listings


Biography

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segmen...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/29 21:15
End of Day Share Price2021/07/29 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.